International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches
- 16 August 2024
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 404 (10455) , 902-906
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor AgonistsNew England Journal of Medicine, 2024
- State Coverage and Reimbursement of Antiobesity Medications in MedicaidJAMA, 2024
- Estimated Sustainable Cost-Based Prices for Diabetes MedicinesJAMA Network Open, 2024
- Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tankAmerican Heart Journal, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Global cost of overweight and obesity will hit $4.32tn a year by 2035, report warnsBMJ, 2023
- GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling offCardiovascular Diabetology, 2021
- The ‘Netflix plus model’: can subscription financing improve access to medicines in low- and middle-income countries?Health Economics, Policy and Law, 2020
- Adding Cost-effectiveness to Define Low-Value CareJAMA, 2018
- Years of Life Lost Due to ObesityJAMA, 2003